← Back to screener

PTC THERAPEUTICS, INC. PTCT

Rank #1690 · Nasdaq · $0.5B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
44.2
P/E
-0.8
P/B
-1.43
ROE
180.5%
Op. Margin
-46.9%
Debt Ratio
-808%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -0.8x, P/B -1.43x. Ranks in the top 99% of the universe.

Profitability ★★★☆☆
Average

ROE 180.5%. Ranks in the top 44% of the universe.

Safety ★★★★★
Excellent

Debt ratio -808%. Ranks in the top 2% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★☆
Excellent

Revenue growth of 34.2% year over year. Ranks in the top 10% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2013–$0.0B$0.0B$-0.3B–-12
2014–$-0.0B$-0.0B$-0.2B–-6
2015–$-0.0B$-0.1B$-0.1B–-35
2016–$-0.1B$-0.1B$0.1B–102
2017–$-0.2B$-0.2B$0.3B–50
2018$0.2B$-0.1B$-0.1B$0.2B-67.9104
2019$0.2B$-0.1B$-0.1B$0.1B-33.1643
2020$0.3B$-0.1B$-0.1B$0.2B-43.7658
2021$0.3B$-0.2B$-0.3B$0.4B-78.6492
2022$0.4B$-0.4B$-0.4B$0.6B-113.4326
2023$0.5B$-0.4B$-0.5B$0.5B-69.5426
2024$0.7B$-0.4B$-0.6B$0.0B-64.0188752
2025$0.9B$-0.4B$-0.6B$-0.3B-46.9-808

← See the full screener